This Project centers on the VCRC Genetics and Genomics Program and includes a broad range of individual scientific projects exploring i) the genetic basis of vasculitis in terms of disease susceptibility, clinical expression and outcome, and response to treatment;ii) the molecular pathophysiology of vasculitis;and iii) potential biomarkers useful for the management of these complex diseases. The recent history of genetics research in rare diseases makes it clear that only through collaboration and cooperation can study populations of meaningful sizes be assembled to conduct genome-wide association studies. The VCRC has established productive collaborations within the international vasculitis communities to conduct such shared genetic research, and also to conduct candidate gene studies and to perform exome sequencing to identify genes containing rare variants. Genomic DNA has been obtained from the >1700 patients already enrolled in VCRC studies, and that number will increase greatly during the next 5 years. Gene expression profiling and epigenetics provide complementary insights into the pathophysiology of disease and can also be used to identify biomarkers of important clinical outcomes. RNA already collected from two VCRC clinical trials will be analyzed for this purpose. The existing protocols for sample collection in the VCRC Longitudinal Studies can easily be adapted to collect DNA (epigenetics) and RNA (gene expression) longitudinally.
The Specific Aims of this Project are to: 1) continue to collect genomic DNA and linked comprehensive clinical data from patients with multiple forms of vasculitis to conduct large-scale collaborative genetics studies;2) conduct a series of candidate gene analyses and genome-wide association studies;3) conduct studies of exome sequencing in order to identify genes with rare variants associated with risk of vasculitis;4) study gene expression profiles from the whole blood of patients with vasculitis during active disease and remission, to identify signatures and molecular pathways related to disease activity, response to therapy, and/or long-term prognosis;and 5) study DNA methylation patterns (epigenetics) in white blood cells to gain insight into pathophysiology of vasculitis and to investigate another potential source of biomarkers useful for diagnosis or prognosis.

Public Health Relevance

The Vasculitis Clinical Research Consortium (VCRC) is an extensive infrastructure that allows experts in multiple centers to collaborate on research in vasculitis, a group of rare and serious diseases that feature inflammatory destruction of blood vessels. The VCRC provides an important contribution to international efforts to use state-of-the-art technology to determine the contributions of genetics and gene expression to the cause and course of vasculitis.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
2U54AR057319-12
Application #
8909280
Study Section
Special Emphasis Panel (ZTR1-CI-8 (01))
Program Officer
Wang, Yan Z
Project Start
2014-09-01
Project End
2019-08-31
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
12
Fiscal Year
2014
Total Cost
$111,376
Indirect Cost
$11,347
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Merkel, Peter A; Xie, Gang; Monach, Paul A et al. (2017) Identification of Functional and Expression Polymorphisms Associated With Risk for Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis. Arthritis Rheumatol 69:1054-1066
Langford, Carol A; Cuthbertson, David; Ytterberg, Steven R et al. (2017) A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Takayasu Arteritis. Arthritis Rheumatol 69:846-853
Milman, N; Boonen, A; Tugwell, P et al. (2017) Clinicians' perspective on key domains in ANCA-associated vasculitis: a Delphi exercise. Scand J Rheumatol 46:112-117
Langford, Carol A; Cuthbertson, David; Ytterberg, Steven R et al. (2017) A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis. Arthritis Rheumatol 69:837-845
Carmona, F David; Coit, Patrick; Saruhan-Direskeneli, G├╝her et al. (2017) Analysis of the common genetic component of large-vessel vasculitides through a meta-Immunochip strategy. Sci Rep 7:43953
Selewski, David T; Thompson, Aliza; Kovacs, Sarrit et al. (2017) Patient-Reported Outcomes in Glomerular Disease. Clin J Am Soc Nephrol 12:140-148
Oommen, Esha; Hummel, Amber; Allmannsberger, Lisa et al. (2017) IgA antibodies to myeloperoxidase in patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Clin Exp Rheumatol 35 Suppl 103:98-101
Gopaluni, Seerapani; Smith, Rona M; Lewin, Michelle et al. (2017) Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial. Trials 18:112
Carmona, F David; Vaglio, Augusto; Mackie, Sarah L et al. (2017) A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. Am J Hum Genet 100:64-74
Sreih, Antoine G; Alibaz-Oner, Fatma; Kermani, Tanaz A et al. (2017) Development of a Core Set of Outcome Measures for Large-vessel Vasculitis: Report from OMERACT 2016. J Rheumatol 44:1933-1937

Showing the most recent 10 out of 72 publications